The sBLA filing for ATEV in dialysis access in H2 2026 is the primary catalyst; monitor FDA acceptance and any advisory committee meeting dates. The $57.5M capital raise and restructuring provide runway, but the company remains pre-profitability with high cash burn. Watch for further clinical data updates and potential partnership or DoD procurement developments.
Price Chart
Executive Summary
Humacyte reported Q2 2026 EPS of -$0.09, beating consensus of -$0.10 by 12.9%, with Symvess product revenue of $0.4M (up from $0.1M YoY). The key catalyst is the planned sBLA filing for ATEV in dialysis access in H2 2026, supported by breakthrough Phase 3 results, and FDA acceptance of an IND for CTEV in CABG. The company also raised $57.5M in a June 2026 public offering and implemented a restructuring to save ~$14.3M in 2026, but net loss widened to $36.8M for the quarter and cash burn remains high.
Key Financial Metrics
Key Facts
- Q2 2026 EPS -$0.09 beat consensus -$0.10 by 12.9%
- Symvess product revenue $0.4M vs $0.1M YoY
- Planned sBLA filing for ATEV in dialysis access in H2 2026
- Breakthrough V012 Phase 3 results: ATEV outperformed AV fistula in female dialysis patients
- FDA accepted IND for first-in-human CTEV study in CABG; Phase 2a expected Q3 2026
- Raised $57.5M gross proceeds in June 2026 public offering
- Restructuring to reduce headcount by ~45 employees, saving ~$14.3M in 2026
- Cash, cash equivalents and restricted cash of $80.3M as of June 30, 2026
- Net loss $36.8M for Q2 2026 vs $37.7M in Q2 2025
Financial Impact
EPS beat of 12.9% on consensus -$0.10; Symvess revenue up 300% YoY to $0.4M; net loss $36.8M; cash position $80.3M
Risk Factors
- Regulatory risk: sBLA may not be accepted or approved by FDA
- Commercial risk: Symvess adoption may not accelerate as expected
- Cash burn: $80.3M cash may not be sufficient to reach profitability without further dilution
- Clinical risk: CTEV Phase 2a results may not replicate preclinical success
- Competitive risk: existing dialysis access options (AV fistula, grafts) may limit ATEV adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343502 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4010 (−8.86%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4010 (−45.43%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4010 (−44.15%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4010 (−61.99%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4010 (+61.99%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4010 (−62.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers